Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Liabilities (2018 - 2025)

Historic Total Liabilities for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $804966.0.

  • BioNexus Gene Lab's Total Liabilities fell 4990.51% to $804966.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $804966.0, marking a year-over-year decrease of 4990.51%. This contributed to the annual value of $2.1 million for FY2024, which is 2118.92% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Total Liabilities is $804966.0, which was down 4990.51% from $1.9 million recorded in Q2 2025.
  • BioNexus Gene Lab's Total Liabilities' 5-year high stood at $3.1 million during Q1 2021, with a 5-year trough of $804966.0 in Q3 2025.
  • For the 5-year period, BioNexus Gene Lab's Total Liabilities averaged around $1.9 million, with its median value being $1.8 million (2024).
  • In the last 5 years, BioNexus Gene Lab's Total Liabilities soared by 322406.13% in 2021 and then crashed by 4990.51% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Total Liabilities stood at $2.4 million in 2021, then dropped by 13.34% to $2.1 million in 2022, then decreased by 16.06% to $1.7 million in 2023, then rose by 21.19% to $2.1 million in 2024, then plummeted by 61.87% to $804966.0 in 2025.
  • Its last three reported values are $804966.0 in Q3 2025, $1.9 million for Q2 2025, and $1.7 million during Q1 2025.